BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 38639944)

  • 21. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma.
    García-Reyes B; Kretz AL; Ruff JP; von Karstedt S; Hillenbrand A; Knippschild U; Henne-Bruns D; Lemke J
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The next "sweet" spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection.
    Xu Y; Wang Y; Höti N; Clark DJ; Chen SY; Zhang H
    Mass Spectrom Rev; 2023 Mar; 42(2):822-843. PubMed ID: 34766650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CT Abnormalities of the Pancreas Associated With the Subsequent Diagnosis of Clinical Stage I Pancreatic Ductal Adenocarcinoma More Than 1 Year Later: A Case-Control Study.
    Toshima F; Watanabe R; Inoue D; Yoneda N; Yamamoto T; Sasahira N; Sasaki T; Matsuyama M; Minehiro K; Tateishi U; Gabata T
    AJR Am J Roentgenol; 2021 Dec; 217(6):1353-1364. PubMed ID: 34161128
    [No Abstract]   [Full Text] [Related]  

  • 24. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.
    Yang S; He P; Wang J; Schetter A; Tang W; Funamizu N; Yanaga K; Uwagawa T; Satoskar AR; Gaedcke J; Bernhardt M; Ghadimi BM; Gaida MM; Bergmann F; Werner J; Ried T; Hanna N; Alexander HR; Hussain SP
    Cancer Res; 2016 Jul; 76(13):3838-50. PubMed ID: 27197190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of an in vitro 3D PDAC stroma rich spheroid model.
    Ware MJ; Keshishian V; Law JJ; Ho JC; Favela CA; Rees P; Smith B; Mohammad S; Hwang RF; Rajapakshe K; Coarfa C; Huang S; Edwards DP; Corr SJ; Godin B; Curley SA
    Biomaterials; 2016 Nov; 108():129-42. PubMed ID: 27627810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.
    Shi Y; Gao W; Lytle NK; Huang P; Yuan X; Dann AM; Ridinger-Saison M; DelGiorno KE; Antal CE; Liang G; Atkins AR; Erikson G; Sun H; Meisenhelder J; Terenziani E; Woo G; Fang L; Santisakultarm TP; Manor U; Xu R; Becerra CR; Borazanci E; Von Hoff DD; Grandgenett PM; Hollingsworth MA; Leblanc M; Umetsu SE; Collisson EA; Scadeng M; Lowy AM; Donahue TR; Reya T; Downes M; Evans RM; Wahl GM; Pawson T; Tian R; Hunter T
    Nature; 2019 May; 569(7754):131-135. PubMed ID: 30996350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma.
    Chang DZ; Ma Y; Ji B; Wang H; Deng D; Liu Y; Abbruzzese JL; Liu YJ; Logsdon CD; Hwu P
    Clin Cancer Res; 2011 Nov; 17(22):7015-23. PubMed ID: 21976550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation of Induced Pluripotent Stem Cell-Like Lines from Human Pancreatic Ductal Adenocarcinoma.
    Kim J; Zaret KS
    Methods Mol Biol; 2019; 1882():33-53. PubMed ID: 30378042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
    Zhang L; Yao J; Li W; Zhang C
    Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.
    LaConti JJ; Laiakis EC; Mays AD; Peran I; Kim SE; Shay JW; Riegel AT; Fornace AJ; Wellstein A
    BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S1. PubMed ID: 25923219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New-Onset or Exacerbation of Diabetes Mellitus Is a Clue to the Early Diagnosis of Pancreatic Cancer.
    Takikawa T; Kikuta K; Kume K; Hamada S; Miura S; Yoshida N; Hongo S; Tanaka Y; Matsumoto R; Sano T; Ikeda M; Iseki M; Unno M; Masamune A
    Tohoku J Exp Med; 2020 Dec; 252(4):353-364. PubMed ID: 33342915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics and treatment analysis of pancreatic acinar cell carcinoma: A single institutional comparison to pancreatic ductal adenocarcinoma.
    Huang X; Li M; Zhang L; Xiong J; Lu H; Tian B
    Surg Oncol; 2021 Jun; 37():101528. PubMed ID: 33611029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma.
    Acier A; Godard M; Gassiot F; Finetti P; Rubis M; Nowak J; Bertucci F; Iovanna JL; Tomasini R; Lécorché P; Jacquot G; Khrestchatisky M; Temsamani J; Malicet C; Vasseur S; Guillaumond F
    Commun Biol; 2021 Aug; 4(1):987. PubMed ID: 34413441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathogenesis of pancreatic cancer: lessons from animal models.
    Murtaugh LC
    Toxicol Pathol; 2014 Jan; 42(1):217-28. PubMed ID: 24178582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pancreatic fibrosis, acinar atrophy and chronic inflammation in surgical specimens associated with survival in patients with resectable pancreatic ductal adenocarcinoma.
    Korpela T; Ristimäki A; Udd M; Vuorela T; Mustonen H; Haglund C; Kylänpää L; Seppänen H
    BMC Cancer; 2022 Jan; 22(1):23. PubMed ID: 34980011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the Origin of Pancreatic Cancer: Molecular Tumor Subtypes in Perspective of Exocrine Cell Plasticity.
    Backx E; Coolens K; Van den Bossche JL; Houbracken I; Espinet E; Rooman I
    Cell Mol Gastroenterol Hepatol; 2022; 13(4):1243-1253. PubMed ID: 34875393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High HDAC9 is associated with poor prognosis and promotes malignant progression in pancreatic ductal adenocarcinoma.
    Li H; Li X; Lin H; Gong J
    Mol Med Rep; 2020 Feb; 21(2):822-832. PubMed ID: 31974610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.
    Gomez-Chou SB; Swidnicka-Siergiejko AK; Badi N; Chavez-Tomar M; Lesinski GB; Bekaii-Saab T; Farren MR; Mace TA; Schmidt C; Liu Y; Deng D; Hwang RF; Zhou L; Moore T; Chatterjee D; Wang H; Leng X; Arlinghaus RB; Logsdon CD; Cruz-Monserrate Z
    Cancer Res; 2017 May; 77(10):2647-2660. PubMed ID: 28249896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunologic Strategies in Pancreatic Cancer: Making
    Ullman NA; Burchard PR; Dunne RF; Linehan DC
    J Clin Oncol; 2022 Aug; 40(24):2789-2805. PubMed ID: 35839445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.